FDA Approves Voranigo (vorasidenib) for the Treatment of Grade 2 IDH-Mutant Glioma
FDA approves Voranigo (vorasidenib), an IDH1 and IDH2 inhibitor, for treating Grade 2 IDH-mutant glioma in patients 12+ years old post-surgery. Voranigo offers a once-daily pill for disease management, with Phase 3 INDIGO trial results showing significant progression-free survival extension and safety.
Related Clinical Trials
Highlighted Terms
Related News
FDA Approves Voranigo (vorasidenib) for the Treatment of Grade 2 IDH-Mutant Glioma
FDA approves Voranigo (vorasidenib), an IDH1 and IDH2 inhibitor, for treating Grade 2 IDH-mutant glioma in patients 12+ years old post-surgery. Voranigo offers a once-daily pill for disease management, with Phase 3 INDIGO trial results showing significant progression-free survival extension and safety.